Answers are grounded in this paper and cite their sources.
Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new advances and approaches. Among the multiple options of immunotherapy, bispecific antibodies (bsAbs) represent a novel thoughtful approach. These drugs integrate the action of the immune system in a strategy to redirect the activation of innate and adaptive immunity toward specific antigens and specific tumor locations. Here we discussed some basic aspects of the design and function of bsAbs, their main challenges and the state-of-the-art of these molecules in the treatment of hematological and solid malignancies and future perspectives.
No takes yet. Share an insight, caveat, or question.
Ordóñez‐Reyes et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: